{"brief_title": "A Double-Blind Study to Evaluate the Safety and Pharmacokinetics of L-Ofloxacin (RWJ 25213) in Subjects With HIV Infection", "brief_summary": "To determine the safety and pharmacokinetics of L-ofloxacin (RWJ 25213) in patients with HIV infection.", "condition": ["HIV Infections"], "intervention_type": ["Drug"], "intervention_name": ["Levofloxacin"], "criteria": "Inclusion Criteria Patients must have the following: HIV infection. Exclusion Criteria Co-existing Condition: Patients with the following symptoms or conditions are excluded: - Active opportunistic infection or neoplasm. - High likelihood of death during study. - Significant ophthalmologic, renal, hepatic, cardiovascular, hematologic, neurologic, psychiatric,respiratory, or metabolic disease. - Donation of > 1 unit blood or acute loss of blood within one month of study entry. Patients with the following prior conditions are excluded: - History of opportunistic infection. - Previous allergic reaction to ciprofloxacin, norfloxacin, or any other quinolone. Prior Medication: Excluded: Use of any investigational agent within 7 days of entry into study. Use of any medication within 3 days prior to entry (7 days for AZT). Alcohol or drug abuse.", "gender": "Male", "minimum_age": "18 Years", "maximum_age": "N/A", "healthy_volunteers": "No", "keyword": "Acquired Immunodeficiency Syndrome", "mesh_term": ["Infection", "Communicable Diseases", "HIV Infections", "Acquired Immunodeficiency Syndrome", "Levofloxacin", "Ofloxacin"], "id": "NCT00002249"}